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(sr-mRNA) in the skin or muscle using electroporation is effec-
tive but hampered by low repeatability. In this manuscript, we
demonstrated that intradermal electroporation of sr-mRNA in
combination with a protein-based RNase inhibitor increased
the expression efficiency, success rate, and repeatability of
the data. The RNase inhibitor should be added just before
administration because storage of the inhibitor together with
the sr-mRNA at 80C resulted in a partial loss of the benefi-
cial effect. Furthermore, the location of intradermal electropo-
ration also had a major effect on the expression of the
sr-mRNA, with the highest and longest expression observed
at the tail base of the mice. In contrast with previous work,
we did not observe a beneficial effect of calcium ions on the
efficacy of naked sr-mRNA after intradermal injection. Finally,
another important finding was that the traditional representa-
tion of in vivo bioluminescence data as means in logarithmic
graphs can mask highly variable data. A more truthful repre-
sentation can be obtained by showing the individual data
points or by displaying median values in combination with
interquartile ranges. In conclusion, intradermal sr-mRNA elec-
troporation can be improved by adding an RNase inhibitor and
injecting at the tail base.
INTRODUCTION
In their renowned work of 1990, Wolff et al.1 showed that intramus-
cular injection of naked synthetic mRNA results in successful
expression. However, despite this promising observation, the field
of non-viral gene delivery has long been dominated by pDNA-based
vectors. mRNA was not considered as an option because the insta-
bility of mRNA was perceived as insurmountable. Additionally, the
large-scale commercial production and inherent innate immunoge-
nicity of synthetic mRNA were also considered important barriers
in the development of mRNA therapeutics.2,3 However, during the
past years most of these issues have been solved, and mRNA is
currently widely examined for vaccination, protein (replacement)
therapy, gene editing, and stem cell reprogramming applications in
preclinical4–7 and clinical studies.7–10 The initial preclinical studies388 Molecular Therapy: Nucleic Acids Vol. 17 September 2019 ª 2019
This is an open access article under the CC BY-NC-ND license (httpwith mRNA mainly involved the local administration of naked
mRNA. Although this resulted in effective protein expression and
immunization, the expression and biological effects were often very
variable even when combined with electroporation.11–16 In more
recent studies it has been shown that non-viral carriers can reduce
the (biologic) variation and increase the efficacy of mRNA therapeu-
tics.11,14,16,17 However, a drawback of non-viral carriers is that they
may cause in vivo toxicity,18–21 potentiate the inherent innate immu-
nity of synthetic mRNA,22,23 and make the commercial production
and registration of mRNA therapeutics more complicated.
We have recently found that intradermal electroporation of a
naked self-replicating mRNA (sr-mRNA) shows, in line with other
studies,13,15 a very variable expression.We hypothesized that degrada-
tion of the naked mRNA by skin-resident ribonucleases (RNases) is
responsible for this effect, and that RNase inhibitors may increase
the efficacy and repeatability of naked mRNA after intradermal elec-
troporation. RNases are present in almost all biological fluids.24 High
amounts of RNases are also found on the skin, where they ensure pro-
tection of the epithelial barrier against pathogens.25 Several molecules
that inhibit RNases have been described.26–28 A very effective and
frequently used RNase inhibitor is the placental RNase inhibitor,
which is a natural occurring protein that noncompetitively inhibits
a broad spectrum of RNases.29,30 Here, we evaluated whether this
protein-based RNase inhibitor can increase the efficacy and repeat-
ability of sr-mRNA after intradermal electroporation. The protein-
based RNase inhibitor was either added just before storage of the
sr-mRNA at 80C or just before injection. Moreover, we injected
the sr-mRNA at the flank, as well as at the tail base, because it has
been reported that the location of injection can affect the efficacy ofThe Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Schematic Representation of the sr-mRNA
and Its Replication
The sr-mRNA starts at its 50 endwith a cap1, a 50 UTR, and
the sequences of the non-structural proteins (nsP1–4) of
Venezuelan equine encephalitis virus (VEEV). These non-
structural proteins are translated as a polyprotein that
forms a replicase (brown). The non-structural proteins are
followed by a subgenomic promoter (SGP, red), which
starts in nsP4. The sequence of the protein(s) of interest
(blue) can be found behind the SGP. In this work, the
protein of interest was firefly luciferase. At the 30 end, an
UTR and a polyA tail are present. When the sr-mRNA
arrives in the cytosol, the nsP1–4 polyprotein is translated
and cleaved by nsP2 to generate the early replication
complex (replicase), which consists of nsP1–3 and asso-
ciated nsP4. In a later phase, nsP1–3 is also cleaved,
and the individual nsPs join together to form the cleaved
replicase. Three promoter elements (PEs) trigger the
replicase and cleaved replicase to generate, respectively,
complementary minus-RNA strands and new copies of
the original genomic RNA starting from the minus-RNA
strands. In addition, the SGP triggers the cleaved replicase
to produce an excessive amount of subgenomic RNAs.
www.moleculartherapy.orgmRNA.31,32 Both areas drain to the same lymph nodes,33 but the skin
differs considerably regarding thickness, functionality, and gene
expression at these sites.34,35 In another effort to increase the efficacy
of intradermal injected mRNA, we also added calcium ions to the
sr-mRNA that was dissolved in a calcium- and magnesium-free phos-
phate buffer. Thismaneuver was based on the observation that the cal-
cium ions in Ringer lactate are responsible for the significant increase
of luciferase expression after naked mRNA injection in the skin.32
RESULTS
Inhibition of RNases Increases the Repeatability and Efficacy of
sr-mRNA after Intradermal Electroporation
mRNA is a rather unstable molecule that is rapidly degraded by
RNases that are abundantly present in the body. Therefore, we
hypothesized that the efficacy of naked mRNA therapeutics after
intradermal electroporation can be increased by adding an RNase in-
hibitor. In this study, we used a sr-mRNA based on Venezuelan
equine encephalitis virus (VEEV) (Figure 1). Without RNase inhibi-
tor the luciferase expression after intradermal electroporation of
this sr-mRNA is extremely variable, and a successful expression
was obtained in only two out of six administrations (Figure 2A).
An intradermal electroporation of sr-mRNA was considered success-
ful when the luciferase expression generated a radiance above
4  105 photons/s/cm2/steradian (p/s/cm2/sr) during at least four
consecutive days as observed previously.23 Supplementation of
the sr-mRNA just before injection with 0.33 or 1.0 U RNase
inhibitor/mL increased the percentage of successful administrations
to, respectively, 67% and 100% (total number of administrations
was six; Figures 2B and 2C). Interestingly, the RNase inhibitor not
only increased the number of effective administrations, but also
drastically reduced the variation of the luciferase expression in the
different injection spots (Figure 2C).Remarkably, a lower success rate (5 out of 6 injections were
successful) and more variable results were obtained when the RNase
inhibitor (1.0 U/mL) was added to the sr-mRNA before storage at
80C instead of immediately before injection (Figure 2C versus 2D).
Next, we calculated the mean bioluminescence signals of the data in
Figure 2. When we plot these means with their SEM on a logarithmic
y axis, as is usually done with in vivo bioluminescence signals from
reporters, it becomes clear that this way of representing the data
masks the strong variability of the data shown in especially Figures
2A, 2B, and 3A. Indeed, based on Figure 3A (green versus red curve),
one would conclude that the RNase inhibitor has only a minor and
non-significant beneficial effect on the expression efficacy. However,
by plotting the median instead of the mean values, a more faithful
representation of the data is obtained (Figure 3B).
The Efficacy of Intradermal sr-mRNA Electroporation Is
Location Dependent
The skin is a large organ with regional variances in thickness, cell-type
density, and perfusion that might influence the expression of genetic
vectors.36 Because there is a clear difference between the skin charac-
teristics at the flank and the tail base,34,35 we decided to compare the
expression kinetics of sr-mRNA after intradermal electroporation at
these two locations. Intradermal electroporation of sr-mRNA in the
tail base caused a significantly higher and longer luciferase expression
compared with intradermal electroporation in the flank (Figures 4A
and 4B).
In more detail, at the plateau, the luciferase expression at the tail base
was 4-fold higher and the plateau lasted twice as long (6 versus
12 days) compared with intradermal electroporation in the flank.
Additionally, it took about 2 months before the luciferase expression
at the tail base disappeared, whereas the expression at the flankMolecular Therapy: Nucleic Acids Vol. 17 September 2019 389
Figure 2. Effect of the RNase Inhibitor on Luciferase
Expression after Intradermal Electroporation of
sr-mRNA in the Flank of Mice
(A–D) Five micrograms of luciferase encoding sr-mRNA
dissolved in 50 mL PBS was supplemented with either
0 (A), 0.33 (B), or 1.0 U/mL (C and D) of RNase inhibitor.
In (B) and (C), the RNase inhibitor was added to the
sr-mRNA just before administration, whereas in (D), the
RNase inhibitor (1.0 U/mL) was added to the sr-mRNA
before storage at 80C. The graphs show the individual
expression profiles in each of the six injection spots
(n = 6).
Molecular Therapy: Nucleic Acidsvanished already after 1 month. Although the variability of the data
after intradermal electroporation in the tail base was slightly higher
than after intradermal electroporation in the flank, it stayed within
acceptable limits. To estimate the overall protein expression, we
calculated the area under the curve (AUC) of the curves shown in
Figure 4C and found a 5-fold higher median expression after injection
at the tail base (Figure 4D).
Effect of Calcium Ions on the Efficacy of sr-mRNA after
Intradermal Administration
Probst et al.32 reported that the efficacy of naked mRNA after intra-
dermal injection can be drastically increased by using Ringer lactate
buffer instead of PBS (without calcium and magnesium). Addition-
ally, they demonstrated that the Ca2+ ions present in the Ringer
lactate were responsible for this effect.32 Therefore, we wondered
whether addition of Ca2+ ions could improve the transfection of
naked sr-mRNA after intradermal injection without using electropo-
ration. To this end, sr-mRNA dissolved in calcium, and magnesium-
free PBS was supplemented with 3 mEq/L Ca2+ ions, which is similar
to the concentration of this ion in Baxter’s Ringer lactate solution.
However, as shown in Figure 5, addition of Ca2+ ions to sr-mRNA
did not increase its transfection efficacy after intradermal injection.
On the contrary, even a small drop in expression was observed (Fig-
ure 5A). Also, the number of successful injections was lower when
Ca2+ ions were added (4 out of 6 versus 5 out of 6; Figures 5B and
5C). In contrast, the expression of naked sr-mRNA was significantly
increased by electroporation as demonstrated by the green curve in
Figure 5A.
Size and zeta potential measurements indicated that addition of
Ca2+ ions to sr-mRNA resulted in the formation of nanoparticles.
In more detail, the zeta potential of sr-mRNA decreased from390 Molecular Therapy: Nucleic Acids Vol. 17 September 20197 ± 4 to 29 ± 1 mV when PBS was supple-
mented with Ca2+ ions. Additionally, the size
of the sr-mRNA slightly increased upon addi-
tion of the Ca2+ ions (Table S1).
DISCUSSION
Our data reveal that supplementation of naked
sr-mRNA with an RNase inhibitor just before
intradermal electroporation resulted in a70-fold increase of the median total luciferase expression (Figure S1).
The latter was obtained by calculating the median of the AUCs of the
individual curves in Figures 2A and 2C. The addition of the RNase
inhibitor also improved the success rates of the administration pro-
cedure (from 2 out of 6 to 6 out of 6 successful expressions; Figures
2A and 2C) and the repeatability of the data (Figure 2C). These bene-
ficial effects of the RNase inhibitor were less pronounced after
intradermal injection of sr-mRNA in the absence of electroporation
(Figure S2), where a better repeatability was seen in only the first
4 days. To inhibit endogenous RNases, we used a protein-based
RNase inhibitor derived from human placenta. In the past, Phua
et al.31 also evaluated this RNase inhibitor, but found that addition
of this inhibitor to naked mRNA did not increase nor decrease
its efficacy. This discrepancy between both studies is likely due to
the difference in the pH of the buffers. In the work of Phua et al.,31
the naked RNA and the RNase inhibitor were dissolved in an
acidic buffer with pH 5, whereas we used PBS at pH 7.4. This differ-
ence is very important because the inhibitor capacity of the human
placental RNase inhibitor is maximal between pH 7 and 8.37
Moreover, the inhibitor starts to lose its RNase blocking capacities
at a pH below 6.38 The pH-dependent efficacy of this protein-
based RNase inhibitor is not surprising because electrostatic interac-
tions are involved in the binding of the RNase inhibitor (negatively
charged at physiologic pH) with RNases (positively charged at
physiologic pH).39 Based on the sequence of the human placental
RNase inhibitor used in the work of Phua et al.,31 we calculated
that it has an isoelectric point of 4.8 (UniProt: P13489).40 Conse-
quently, at the pH used by Phua et al.31 (i.e., pH 5), this protein-based
RNase inhibitor will be almost neutral and hence largely lose its
RNase binding and blocking capacities. This most likely explains
why they did not observe any beneficial effect of the RNase inhibitor
in their paper.
Figure 3. TheUse ofMedian Values and Interquartile
Ranges Is More Appropriate for Presenting Highly
Variable Bioluminescence Data
(A and B) The mean (± SEM) (A) and median (± interquartile
range) (B) bioluminescence signals obtained after intra-
dermal electroporation of luciferase encoding sr-mRNA in
the absence or presence of RNase inhibitor. Five micro-
grams of luciferase encoding sr-mRNA dissolved in 50 mL
PBS was injected in the flanks of mice and immediately
electroporated. The green curves show the luciferase
expression of the sr-mRNA without supplementation with
RNase inhibitor. The blue and red curves depict the lucif-
erase expression after adding, respectively, 0.33 and
1.0 U/mL RNase inhibitor to the sr-mRNA just before in-
jection. The black curves represent the luciferase expres-
sion after adding 1.0 U/mL RNase inhibitor before storage
at 80C. (n = 6). Due to the high variation in luciferase
expression, no significant differences were observed be-
tween the groups.
www.moleculartherapy.orgIn Figure 2A, we noticed that one unsuccessful injection suddenly
gave rise to a moderate luciferase expression after day 4. Although
the exact reason is not known, we speculate that in this specific
case many of the sr-mRNAs were degraded by extracellular RNases,
and that hence only a limited amount of sr-mRNAs entered the cyto-
plasm. We assume that this higher amount of degraded mRNAs
triggered a stronger innate immune response than usual. This intense
innate response caused, probably 6–12 h after sr-mRNA administra-
tion, a premature arrest of the translation of the replicase. Neverthe-
less, over the next hours and days the replicase succeeded: (1) to
replicate the few intact copies of the sr-mRNA and (2) to generate
many copies of the luciferase encoding subgenomic RNA. However,
this did not directly result in a luciferase expression because the
elicited innate immune response still inhibited the translation of the
subgenomic RNAs. To explain the sudden rise of the luciferase, we
speculate that the elicited factors causing translation block steadily
dropped, and that after day 4 they became below the “translation
inhibition threshold.” This allowed a massive translation of the
generated subgenomic RNA.
Surprisingly, we observed that the beneficial effect of the protein-based
RNase inhibitorwas partly lostwhen it was added to the sr-mRNAprior
to storage at 80C. This brings us to another important pitfall when
using human placental RNase inhibitor to protect mRNA therapeutics
against RNases. In laboratory protocols involving the manipulation of
isolated RNA, it is often stated that, e.g., human placental RNase inhib-
itor can be added to the isolatedRNAbefore freezing. The stock solution
of the protein-based RNase inhibitor (40 U/mL) is stored at20C and
contains 50% glycerol, which prevents freezing of the stock solution at
20C. However, by adding the advised amount of 1.0 U of RNase
inhibitor per microliter RNA, a 40-fold dilution of the RNase inhibitor
occurs. Consequently, this mixture will freeze below 0C and hence the
protein-based RNase inhibitor will be exposed to freeze denaturation.
This most likely explains the lower success rate and higher variation
of the data in Figure 2D when we used RNase inhibitor-supplemented
sr-mRNA solutions that had been stored at 80C. Therefore, to pro-tect naked mRNA against RNases in the body, it is advised to add the
human placental RNase inhibitor just before administration and not
store it together with the mRNA in the freezer. Our study also shows
that the beneficial effect of the RNase inhibitor on RNA expression
was dose dependent (Figures 2B and 2C). The optimal dose was
1 U/mL, because increasing the dose to 3 U/mL did not affect RNA
expression (Figure S3). A unit of this inhibitor is defined as the amount
that is necessary to inhibit the activity of 5 ng of RNaseA by 50%.When
using 50 U in 50 mL of injection solution, as in our experiments, this
comes down to the potential of inhibiting 250 ng of RNase A by 50%.
We also demonstrated that the interpretation of highly variable in vivo
bioluminescence data is influenced by the presentation of the data. In
the literature, in vivo bioluminescence data of vectors encoding, e.g.,
luciferase are frequently displayed as means accompanied by error
bars representing the SEM.4,15,17,31,41 The value of in vivo biolumines-
cence signals ranges in general between 104 and 109. Therefore, a
few high data points in a series of bioluminescence data can drasti-
cally increase the mean, whereas low signals will have almost no effect
on the value of the mean. The error bars on graphs that represent
bioluminescence data should depict this variability. However, in vivo
bioluminescence data are represented on graphs with a logarithmic
y-axis. Consequently, the upper error bar in such graphs is always
quite small compared with the mean, and the opposite applies for
the lower error bar. Additionally, in many papers the error bar in
these graphs represents the SEM, which makes it even more difficult
for the reader to get an idea of the variability of the data. Therefore, a
more reliable way of presenting in vivo bioluminescence data is
showing all of the individual data points.11,14,32 However, when using
large group samples, graphs often become cluttered, resulting in loss
of clarity. Another good alternative in this case is the use of medians
and interquartile ranges for the representation of the data.
The site where the sr-mRNA is injected in the skin of themice (tail base
versusflank) had adrastic effect on the expression efficacy andduration.
Intradermal electroporation at the tail base resulted in a significant,Molecular Therapy: Nucleic Acids Vol. 17 September 2019 391
Figure 4. Comparison of the Luciferase Expression
Kinetics after Intradermal Electroporation of
sr-mRNA at the Flank or at the Tail Base
(A–D) Five micrograms of sr-mRNA-encoding luciferase
was just before injection supplemented with 1.0 U/mL
RNase inhibitor and after intradermal injection immedi-
ately electroporated. Each curve in (A) and (B) represents
the evolution of the individual bioluminescence signal in
the separate injection spots of the flank (A) or the tail base
(B) (n = 6). (C) The median bioluminescence signal over
time after intradermal electroporation in the flank (blue)
and in the tail base (green) is shown (error bars represent
interquartile range; n = 6). (D) The area under the curve
(AUC) of the curves in (C) and the median AUC (line) are
plotted. Note the differences in the scales of the x axes in
the graphs. **p = 0.0022.
Molecular Therapy: Nucleic Acids5-fold higher overall expression and lasted twice as long comparedwith
administration at the flank. Also, Phua et al.31 found that subcutaneous
injection at the tail base resulted in a higher expression of the mRNA
compared with injection at the base of the ear pinna. To exclude that
the higher luciferase expression at the tail base was due to a better tissue
penetration of the bioluminescent light at the tail base, we intradermally
injected at theflank and tail base an equal amountof 4T1 cells that stably
express luciferase. The bioluminescence signals at both locations were
compared, and no significant differences were observed (Figure S4).
Therefore, we can conclude that the differences in luciferase expression
at the flank and tail base are not due to a better tissue penetration of
the bioluminescent light at the tail base. Hence the differences are really
due to an increased luciferase expression at the tail base.
It has been reported that the efficacy of intradermal or subcutaneous in-
jected naked mRNA can also be improved by dissolving the mRNA in
Ringer lactate buffer. Probst et al.32 found that the Ca2+ ions in Ringer
lactate are causing this increase in expression. However, our study did
not find any beneficial effect of Ca2+ ions on the transfection efficacy
of naked sr-mRNA after intradermal injection without electroporation.
The reason for this discrepancy is not clear, but a possible explanation is
that theCa2+ ionspartly protect themRNAagainst RNases by forming a
complex (particle) withmRNA. In our study, the sr-mRNAwas already
protected because an RNase inhibitor was used, and therefore we prob-
ably could not detect the beneficial effects of the Ca2+ ions. The hypoth-
esis that Ca2+ ions increase the efficacy of naked mRNA by reducing its
degradation by RNase is further supported by the fact that Ca2+ ions
have been reported to inhibit human pancreatic RNase activity.42,43
Conclusions
In conclusion, we found that addition of a protein-based RNase inhib-
itor to sr-mRNA just before intradermal electroporation improved its392 Molecular Therapy: Nucleic Acids Vol. 17 September 2019.
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repeatability and increased the efficacy and
success rate of the sr-mRNA expression. The
beneficial effect of the RNase inhibitors was
partly lost when it was added beforehand and
thus stored together with the sr-mRNA at80C. This can be attributed to a partial degradation of the pro-
tein-based RNase inhibitor by freeze denaturation. In this paper, we
also demonstrated that the traditional representation of in vivo biolu-
minescence data asmean± SEM in logarithmic graphs canmask highly
variable data. A more truthful representation can be obtained by dis-
playing median values in combination with interquartile ranges
Furthermore, in an attempt to increase the translation efficiency o
the mRNA, we demonstrated that the expression of intradermally
electroporated sr-mRNA in the tail base was significantly superior
compared with its expression in the flank. This vast difference empha-
sizes that the location of an intradermal mRNA injection should be
carefully chosen in human clinical trials. Finally, it has been reported
that Ca2+ can increase the efficacy of naked mRNA.32 However, using
RNase inhibitor-supplemented sr-mRNA, we could not confirm this
effect. We speculate that the beneficial effect of calcium in previous




Female wild-type BALB/cJRj mice were purchased from Janvier
(France) or bred in-house in a climate-controlled facility under a
14/10-h light/dark cycle. The mice were kept in individually venti-
lated cages with ad libitum access to feed and water. The described
experiments with mice in this paper were conducted with the
approval of the ethical committee of the Faculty of Veterinary
Medicine, Ghent University (EC 2016/17). At the start of the exper-
iments the mice were between 7 and 10 weeks old.
Plasmids and mRNA Synthesis
The plasmid pTK160 (11,519 bp) used for in vitro transcription (IVT)
of firefly luciferase encoding sr-mRNA (Figure 1) was a kind gift o
Figure 5. The Effect of Calcium Ions on the Expression of Naked sr-mRNA after Intradermal Administration without Electroporation
(A) Median luciferase expression with interquartile range after intradermal injection of sr-mRNA (5 mg) dissolved in PBS (Ca/Mg free) without (blue curve) or with 3mEq/L CaCl2
(red curve). The naked sr-mRNA was supplemented with 1.0 U/mL RNasin just before intradermal injection (six mice per group). The luciferase expression after intradermal
electroporation of 5 mg sr-mRNA (dissolved in Ca/Mg-free PBS, green curve) in the tail base is also shown as a reference. The gray zones display significant differences
between intradermally electroporated sr-mRNA and intradermally injected naked sr-mRNA with or without calcium. *p < 0.05. (B and C) Luciferase expression in the
individual intradermal injection spots of 5 mg sr-mRNA dissolved in PBS (B) or in PBS supplemented with 3 mEq/L CaCl2 (C) (6 mice per group). All intradermal injections in
these graphs were performed at the tail base.
www.moleculartherapy.orgDr. Tasuku Kitada and Prof. Ron Weiss (Massachusetts Institute of
Technology, Cambridge, MA, USA). The plasmid is derived from
VEEV strain TC-83 containing a substitution in the 50 UTR
(r.3a>g) and in nsP2 (p.Q739L). The sequence coding for the struc-
tural proteins was replaced by the reporter gene luc2. This plasmid
was constructed using standard Gateway cloning procedures and
contains, besides the reporter genes, also VEEV-derived 50 and 30
UTRs. E. coli bacteria containing the plasmids were cultivated in
lysogeny broth (LB; Invitrogen, MA, USA), and the plasmids were
subsequently isolated using the Plasmid Plus midi kit (QIAGEN,
Germany). mRNA was produced by IVT of I-SceI (NEB, MA,
USA) linearized pTK160 using the MEGAscript T7 Transcription
kit (Life Technologies, MA, USA). Following IVT, the RNA
was treated with DNase I (Invitrogen) and purified using the
RNeasy Mini Kit (QIAGEN), denatured at 65C, and enzymatically
(cap1) capped using the ScriptCap m7G Capping System
(Cellscript, Madison, WI, USA) and ScriptCap 20-O-Methyltransfer-
ase Kit (Cellscript). All mRNAs were purified with the RNeasy Mini
kit (QIAGEN) between two modifications and before in vivo
application. After the final purification, the sr-mRNA was stored
at 80C. The mean hydrodynamic diameter and zeta potential
were determined using a Nano ZS90 (Malvern Pananalytical,
Worcestershire, UK).
Intradermal Delivery of sr-mRNA
Five micrograms of sr-mRNA dissolved in 50 mL PBS (Ca2+ andMg2+
free; Ambion; Thermo Fisher Scientific, MA, USA) was supplemented
with different concentrations of RNase inhibitor (RNasin Plus;
Promega, WI, USA) before storage at 80C or just before injection.
RNasin Plus is a recombinant variant of the human placental RNase
inhibitor that is more resistant toward oxidation than RNase inhibitor
due to the substitution of two cysteine residues (Cys328 and Cys329)
by alanine residues.44 RNasin Plus is a noncompetitive inhibitor of
RNase A, RNase B, and placental RNase.45 Where indicated in theResults, RNase-free CaCl2 (Sigma-Aldrich, Germany) was also added
to the sr-mRNA at a final concentration of 3 mEq/L Ca2+ (as present
in Baxter’s Ringer lactate buffer). Prior to intradermal administration,
the mice were shaved to allow a better exit of the photons produced
during the luciferase-mediated oxidation of luciferin. The sr-mRNA
(5 mg in 50 mL PBS) was intradermally injected at the flanks or at
the tail base of the mice using a 29G insulin needle (VWR, the
Netherlands). Electroporation, when used, was executed immediately
after each injection with a needle array electrode consisting of two
rows of four 2-mm-long needles. The gap between the rows was
4 mm, and within the rows the needles were 1.5 mm apart from
each other (AgilePulse; BTX Harvard Apparatus, MA, USA). Needles
were completely inserted in the skin covering the injection site. The
electroporation has been previously described and involved two short
0.05-ms high-voltage pulses of 450 V with an interval of 300 ms,
followed by eight long low-voltage pulses of 100 V with a duration
of 10 ms and an interval of 300 ms.46 In experiments where sr-mRNA
was supplemented with Ca2+ ions, no electroporation was used,
because it is well known that the combination of Ca2+ ions with elec-
troporation leads to cell death.47–49
Bioluminescence Imaging
To monitor the luciferase expression, we intraperitoneally injected
the mice with 200 mL D-luciferin (15 mg/mL; Gold Biotechnology,
MO, USA), and in vivo bioluminescent imaging was performed
15 min later using an IVIS Lumina II (Perkin-Elmer, Zaventem,
Belgium). The average radiance in the region of interest was deter-
mined using the Living ImageSoftware 4.3.1. In vivo bioluminescence
imaging was repeated at different time points to study the expression
kinetics of the sr-mRNA. Time point 0 in the graphs indicates the
time of administration, and the first imaging time point was 5 h
(0.2 day) after injection. The intradermal injections and biolumines-
cence imaging were performed under gas anesthesia (isoflurane:
5% induction and 2% maintenance).Molecular Therapy: Nucleic Acids Vol. 17 September 2019 393
Molecular Therapy: Nucleic AcidsStatistical Analysis
Statistical analysis was performed with the software GraphPad Prism
6 (GraphPad Software, CA, USA). Longitudinal experiments were
analyzed with repeated-measures two-way ANOVA, followed by
Sidak’s or Tukey’s multiple comparisons test. Differences between me-
dians were analyzed using the non-parametric Mann-Whitney U test.
Differences are found to be significant when the p value is <0.05.
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Fig. S1. Quantification of the effect of different doses of RNase inhibitor on the expression of sr-mRNA after 
intradermal electroporation in the flank of mice. The luciferase expression was quantified by calculating the 
AUCs of the curves in Fig. 2 (n=6). The median of these AUC-values as well as the individual values are shown. 
The median AUC in the absence of RNase inhibitor (green line) increased 70-fold when the RNase inhibitor (1 
units/µl, red line) was added to the sr-mRNA (5 µg/50 µl) just before administration. The data in red and black 
were obtained when the RNase inhibitor was added just before intradermal electroporation of 5 µg luciferase 
encoding sr-mRNA, while the data in blue were obtained with sr-mRNA that had been stored with the RNase 
inhibitor at -80°C. 
 
 
Fig. S2. Effect of RNase inhibitor on the expression of naked sr-mRNA after intradermal administration 
without electroporation. The median bioluminescence signals with interquartile range obtained after intradermal 
injection of naked sr-mRNA with or without RNase inhibitor supplementation. Five microgram of luciferase 
encoding sr-mRNA dissolved in 50 µl PBS (without Ca2+ and Mg2+) was injected at the tail base of mice (n=6). 
The green curve shows the luciferase expression without supplementation with RNase inhibitor, while the red 
curve shows the expression after adding 1.0 units/µl of RNase inhibitor to the sr-mRNA just before injection. No 
significant differences were observed. Only the variation of the expression was clearly higher in the first 4 days 
when no RNase inhibitor was used (green curve). 
 
 
Fig. S3. Increasing the RNase inhibitor dose above 1 unit per microliter sr-mRNA solution did not further 
improve the expression or repeatability. The median bioluminescence signals over time after intradermal 
electroporation of a luciferase encoding sr-mRNA (5 µg/50 µl PBS) to which 1.0 (green curve) or 3.0 units/µl 
(black curve) of RNase inhibitor was added just before injection. No significant differences were observed between 
the groups. Error bars represent interquartile range (n=6). 
 
Fig. S4. Comparison of the penetration of bioluminescent light through the skin of the flank and tail base. 
Mice were intradermally injected at the flank and at the tail base with an equal amount of 4T1 cells (106) that 
stably express luciferase. Directly after administration of the bioluminescent cells, luciferin was intraperitoneal 
injected and 15 minutes later the bioluminescent signals were measured. The graph represents the median 
bioluminescence signals and the individual signals after flank (blue) or tail base (green) administration. No 








Table S1. Effect of calcium ions on the hydrodynamic diameter and zeta potential of sr-mRNA. Ten µg of 
sr-mRNA was dissolved in 100 µl PBS without or with CaCl2 (3mEq/l Ca2+). After 30 minutes of incubation at 
room temperature, the sr-mRNA solutions were diluted with either PBS or CaCl2-containing PBS to 1 ml, keeping 
a constant Ca2+ concentration. Subsequently, the size and zeta potential were measured. 





PBS 4 920 174 
ns 
Ca2+ PBS 6 1155 309 
ZETA POTENTIAL 
(mV) 
PBS 4 -7 4 ** 
p = 0.0028 Ca2+ PBS 9 -29 1 
